

ODB Funding for Mifegymiso

Effective August 10, 2017, Ontario will publicly fund the drug Mifegymiso (combination mifepristone/misoprostol) **DIN 02444038**, for both ODB and non-ODB recipients.

PTS has inserted a custom class **Mifegymiso Reimbursement** on the drug file, along with the corresponding pricing rules.

Submitting Claims for ODB-Eligible Recipients (Bill Codes DB/D5/DL/TR)

The claim submission follows the normal process for submitting claims on the HNS with the following additional information:

- Bill Code : **DB, D5, DL** or **TR**
- Intervention code '**PS**': (Professional Care Services)
- Drug Identification Number (DIN): **02444038**
- Valid Pharmacist ID
- Professional Fee: **\$337.2500** (includes mark-up and dispensing fee)

Submitting Claims for Non-ODB Eligible Recipients

When submitting a claim for a person who does not have ODB coverage, pharmacists must submit the following information:

- Bill Code: **ON** (intervention codes will be automatically inserted)
 - **PS**: Professional Care Services
 - **ML**: Established eligibility coverage (i.e., 1 day of the Plan 'S' coverage)
- Patient Gender: '**F**' = female
- Patient Date of Birth: **Valid YYYYMMDD**
- Patient's **Ontario Health Card** number
- Carrier ID: 'S'
- Drug Identification Number (DIN): **02444038**
- Valid Pharmacist ID
- Professional Fee: **\$337.2500** (includes mark-up and dispensing fee)

Verify the Update

To validate that the update was successful:

1. Open the drug file for DIN **02444038**.
2. Confirm that the Custom Class **Mifegymiso Reimbursement** has been added.

NOTE: If your drug file has not been updated, contact the PTS Customer Care team immediately.



Where can I get more information?

For more information, use the following links:

- http://www.ocpinfo.com/library/practice-related/download/Dispensing_Mifegymiso.pdf
- <http://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2017/63330a-eng.php>
- <http://www.cpso.on.ca/Policies-Publications/Positions-Initiatives/Mifegymiso>
- www.cno.org/en/news/2017/july-2017/what-nps-should-know-about-mifegymiso

